48 results about "Neuropeptide" patented technology

The invention discloses application of Bombyx mori neuropeptide BommoOKAtype4 in preparation of a medicine for inhibiting melanoma cell growth, and belongs to the technical field of medical biology. Aiming at the technical problems that melanoma is high in malignancy degree, easy to transfer and limited in treatment means, and whether the bombyx mori neuropeptide BommoOKAtype4 can directly inhibit the growth of melanoma cells is not clear yet when the bombyx mori neuropeptide BommoOKAtype4 is mainly used for skin whitening before, the invention provides the application of the bombyx mori neuropeptide in preparing the medicine for inhibiting the melanoma cells. According to the silkworm neuropeptide, gene expression and protein functions of melanin synthesis key enzymes TYR, TRP1 and TRP2 are comprehensively inhibited by down-regulating expression of a core transcription factor MITF, so that melanoma cell proliferation is directly inhibited while melanin synthesis is inhibited, and therefore, the silkworm neuropeptide can be used for preparing drugs for treating melanoma and has a wide application prospect. A novel peptide candidate substance is provided for treatment of melanoma.

The invention relates to an anti-epileptic polypeptide coupling medicine and a preparation method and application thereof, the polypeptide coupling medicine comprises an Fmoc protecting group, a permeation accelerating peptide and a cell penetrating peptide which are sequentially connected from the N end to the C end, and the permeation accelerating peptide is connected with an anti-epileptic medicine molecule. According to the invention, by fully utilizing the treatment requirements of epileptic seizure and the technical advantages of intranasal drug delivery, through the collaborative design of the protecting group, the functional polypeptide sequence and the anti-epileptic drug, the defects of poor brain targeting property, easy cyclization of a polypeptide carrier, low intranasal delivery efficiency and the like of the traditional anti-epileptic drug are overcome, non-invasive, efficient and low-toxicity epilepsy treatment is realized, and the application prospect is wide. And the preparation process is simplified, the clinical transformation requirement is met, and meanwhile, a new strategy is provided for non-invasive brain delivery of neuropeptide drugs.

The present invention relates to insect neuropeptide compounds of the family of pyroglutamic peptides and analogs thereof having activity against insects, such as Hemiptera, Diptera, Lepidoptera, Blattaria and / or Coleoptera insects, such as aphids and fruit flies, and their use as insect control agents (e.g. insecticides) and plant protection agents.

The present invention relates to analogues of insect neuropeptides that are active against insects, such as Diptera, Hemiptera, Blattodea and / or Lepidoptera, and to the use of these as insect control agents (e.g., insecticides) and plant protection agents.

The invention relates to the technical field of medicines, in particular to application of a neuropeptide Y1 receptor antagonist in preparation of a hereditary polycystic kidney disease treatment medicine. The neuropeptide Y1 receptor antagonist is selected from a compound BIBO3304 which plays a role in blocking combination of neuropeptide Y (NPY) and a Y1 receptor subtype thereof. On the basis that early-stage histopathology, high-throughput sequencing, cytobiology and molecular biology are combined with in-vitro cell culture and in-vivo animal experiments, the potential treatment effect of the neuropeptide Y1 receptor antagonist in preparation of hereditary polycystic kidney disease treatment drugs is provided, and a new basis is provided for hereditary polycystic kidney disease treatment.

The present invention relates to triple agonists of the GLP1 / GIP / NPY2 receptor. Disclosed are hybrid polypeptides that agonize GIP, GLP-1 and neuropeptide Y2 (NPY2) receptors and their medical use in the treatment of a variety of diseases, conditions or conditions, such as obesity, diabetes and / or NASH. The polypeptides have the general structure Z1-Z2-Z3 wherein Z1 is a hybrid polypeptide that provides GIPR and GLP1R agonism, Z2 is a linker, and Z3 is a polypeptide that provides hY2R agonism.

Failures in establishing trust during international conflict negotiations frequently result in warfare, as ideological differences often cannot be resolved through rational discourse alone. Empathy between opposing parties is essential for building trust, and oxytocin is recognized for its critical role in facilitating empathy, trust, inter-brain synchrony, and cooperative decision-making. However, prevailing scientific studies typically do not differentiate between the cis and trans isomers of oxytocin, despite evidence that only the trans isomer is pharmacologically active. The present invention provides methods for the separation and quantification of oxytocin isomers, with particular emphasis on the trans isomer's function in social synchrony and decision-making within conflict negotiation contexts. Additionally, the invention explores the role of extremely low frequency electromagnetic radiation permeating the human central nervous system interconnecting neurochemical changes among groups. These advances clarify the unique neuropeptide functions of oxytocin and enhance understanding of its impact on cooperation and conflict resolution.

To provide a composition of trophinetide. [Solution] This disclosure describes a compound of formula (I), its stereoisomers, by-compounds, pharmaceutical compositions, and methods for producing such compounds using silylating agents, as well as methods for producing compositions and products produced using such methods. More specifically, this disclosure describes the production of trophinetides and by-products, compositions, and products containing such compounds for pharmaceutical applications for the treatment of neurodegenerative or neurodevelopmental disorders. JPEG2026063085000110.jpg55147

The present invention relates to the medical device and ophthalmological industry, as well as related fields such as dermatology and cosmetics, since the formulation includes natural neuroprotective components. The invention describes an iontophoretic delivery of cannabinoid-based formulations designed for ophthalmic conditions, that comprise pharmaceutically acceptable charged vehicles, including but not limited to cationic surfactants, cyclodextrins, nanoparticles and microspheres, emulsions or liposomes, with control the size distribution, potential, osmolality and pH. In a further embodiment of the invention, the intraocular composition proposed further comprises one or more synergistic agents, including but not limited to neuropeptides, exosomes, mitochondrial-derived peptides, complement inhibitors, senolytics, autophagy enhancers, antioxidants, saffron, and non-steroidal anti-inflammatory pharmaceutical drugs with pharmaceutically acceptable charged vehicle.

The application provides an application of a hair follicle immune homeostasis regulation strategy in treating alopecia diseases. A group of pathological LAMP3 + CCR7 + IL4I1 + DC3 dendritic cell subpopulation. A DC3 dendritic cell subpopulation marker gene Il4i1 Drive conditionally knockout one of the CGRP receptor complexes Calcrl The constructed spontaneous alopecia areata animal model can well simulate the progressive and active hair loss of alopecia areata patients, form stable hair loss patches, and combine with pathological changes such as hair follicle immune cell infiltration, which indicates that the dendritic cell CGRP signal loss is an important inducement for mediating systemic alopecia areata. The application also discloses a pharmaceutical composition or kit for preparing a drug for relieving / treating hair loss, improving hair follicle homeostasis, or enhancing hair growth / black coloration (reducing white hair), which comprises: (a) a JAK kinase inhibitor, and (b) a neuropeptide CGRP or a receptor agonist thereof.

The present invention relates to natural or natural-like analogues of insect pyrokinin neuropeptide [Pyr]-AIMARPQVPRL-[NH2](SEQ ID NO:2) having activity against insects, for example hemipteran, dipteran, lepidopteran, blattodean and / or coleopteran insects, such as aphids, moths and fruit flies, and their use as insect control agents (e.g. insecticides) and plant protection agents.

The invention provides a preparation process of a soothing and repairing type mask, and belongs to the technical field of cosmetics, an intelligent response type cell bionic delivery system is adopted, macrophage membrane vesicles serve as a carrier, a composite repairing kernel, epicatechin gallate, a neuropeptide P substance antagonist and idebenone are wrapped, and by means of the inflammation chemotaxis of a macrophage membrane, the soothing and repairing type mask is prepared. According to the present invention, the active component can actively target the inflammation region, the phase change release core is provided in the weakly acidic microenvironment with the pH value of 5.0-6.0, the targeting property and the permeation efficiency of the active component can be improved, the bottleneck of the traditional passive diffusion can be broken through, and compared with the conventional liposome or nanoparticle, the active component can be accurately delivered to the inflammation core region, the permeation rate can be improved by several times, and the carrier can directly reach the problem core region; according to the method, the utilization rate of effective components is greatly increased, a micro-ecology-immunity-nerve-physical barrier multi-dimensional and systematic synergistic repair network is constructed, full-path fundamental repair from immediate relieving to root strengthening is achieved, and immediate relieving and long-term barrier repair effects are provided.

The present invention relates to peptide compounds that agonize the GIP, GLP-1 and neuropeptide Y2 (NPY2) receptors, agonists, processes for their preparation, pharmaceutical compositions thereof, and their medical use in the treatment and / or prevention of a variety of diseases such as obesity, diabetes, metabolic syndrome, and / or MASH / NASH. The peptide compounds of the invention are suitable for subcutaneous administration.

The application discloses a novel insect short neuropeptide sNPF analogue and application thereof in pests, and relates to the technical field of agriculture; the application provides a structural general formula of the novel insect short neuropeptide sNPF analogue, and the novel insect short neuropeptide sNPF analogue is applied to the prevention and treatment of aphids, thrips, Plutella xylostella and Spodoptera frugiperda. The terminal tyrosine Y, arginine R or leucine L residue is substituted and modified by using hydrophilic, hydrophobic, steric hindrance natural amino acids or unnatural amino acids and other groups on a lead compound, and the obtained novel insect short neuropeptide sNPF analogue can be used in the prevention and treatment of various pests.

The invention discloses a nilaparvata lugens muscle-friendly neuropeptide orcokinin-A and application of the nilaparvata lugens muscle-friendly neuropeptide orcokinin-A. The amino acid sequence of the neuropeptide orcokinin-A is as shown in SEQ ID NO. 2. The dsRNA (dsOKA) of the nilaparvata lugens muscle-friendly neuropeptide orcokinin-A has better gene silencing efficiency, and multiple experiments show that injection of 60ng of dsOKA can lead to incomplete ovarian development of female nilaparvata lugens adults, shortening of oviposition duration, significant reduction of oviposition amount, significant reduction of filial generation number and significant reduction of population growth index. The nilaparvata lugens muscle-friendly neuropeptide orcokinin-A can be used as an important molecular target for preventing and controlling nilaparvata lugens, is expected to fully exert the function of ecological prevention and control while inhibiting pests, and can be widely applied to crop breeding, biopesticide research and development and biological prevention and control.

The invention particularly discloses dendritic poly-L-lysine modified PACAP as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The PACAP-DPL provided by the invention effectively overcomes the defect of insufficient in-vivo stability of natural PACAP on the premise of not weakening the biological function of PACAP, provides a new technical approach for the application of PACAP neuropeptides in Alzheimer's disease, and has good research value and potential application prospect.

The invention relates to a hypertension implant rod and a preparation method thereof, and relates to the technical field of hypertension implant rods, the hypertension implant rod comprises a quick release layer, a slow release layer and a long-acting regulation and control layer from outside to inside, the quick release layer comprises, by mass, 60-70% of bacterial cellulose (BC), 15-25% of polydopamine (PDA), 3-8% of ciprofloxacin, 3-8% of protamine and 4-6% of indapamide, the slow release layer comprises, by mass, 20-30% of a long-acting regulation and control layer, and the long-acting regulation and control layer comprises, by mass, 20-30% of a slow release layer and 20-30% of a long-acting regulation and control layer. The sustained release layer is prepared from 55 to 65 percent of polylactic acid-glycolic acid copolymer, 20 to 30 percent of cross-linked gelatin, 8 to 12 percent of lacidipine and 4 to 6 percent of spirolactone, and the long-acting regulation and control layer is prepared from 65 to 75 percent of L-polylactic acid, 20 to 30 percent of beta-glycine crystal, 3 to 5 percent of silk fibroin (SF), 0.5 to 1.0 percent of calcitonin gene related peptide CGRP and 0.1 to 0.3 percent of neuropeptide Y. The hypertension implant rod can be matched with various treatment cycles through gradient degradation, realizes'on-demand treatment ', is high in biocompatibility, is suitable for subcutaneous implantation, and is convenient and safe to operate.

The present invention relates to analogues of insect neuropeptides having activity against insects, such as hemipteran, dipteran and / or lepidopteran insects, such as aphids and fruit flies, and their use as insect control agents (e.g. insecticides) and plant protection agents.

The present invention relates to insect neuropeptide compounds of the AKH family and analogs thereof having activity against insects, such as hemiptera, diptera, lepidoptera, cockroaches and / or coleopteran insects, such as aphids and fruit flies, and their use as insect control agents (e.g. Insecticides) and plant protection agents.

The present invention provides PYY analogs that are neuropeptide Y2 (NPY2) receptor agonists, their medical use in the treatment and / or prevention of various diseases, conditions, or disorders, such as the treatment and / or prevention of excessive food intake, excess weight, adiposity, metabolic diseases, and other conditions or disorders associated with excess weight or adiposity, such as diabetics and cardiovascular diseases.SOLUTION: The present invention relates to PYY analogues having alanine in position 4, lysine in position 7, QRY as C-terminus and a half-life extending group. The analogs of the present invention are soluble in pH6 and around 7. The invention also relates to pharmaceutical compositions comprising the PYY analogues and to pharmaceutical uses of the analogues.SELECTED DRAWING: None

Intranasal neuropeptide Y (NPY) analogs having D-amino acids, such as [D26-His]-NPY are provided for early intervention to prevent or to treat, to reverse, or reduce symptoms of stress-related impairments such as PTSD, depression, substance abuse, and / or memory deficits following exposure to traumatic or surgical stress.

This invention discloses the application of largemouth bass neuropeptide in the preparation of products for preventing and treating Aeromonas hydrophila infection. The amino acid sequence of the largemouth bass neuropeptide is shown in SEQ ID NO.1. The largemouth bass neuropeptide provided by this invention is a novel antimicrobial peptide that can significantly enhance the ability of largemouth bass to resist Aeromonas hydrophila infection both in vivo and in vitro. It provides a new technical option for the prevention and treatment of Aeromonas hydrophila-related diseases and for achieving "antibiotic-free aquaculture" of largemouth bass. It helps to improve the survival rate of largemouth bass fry, promotes green aquaculture, and has broad application prospects.

The present disclosure relates to use of tear fluid neuropeptide Y (NPY) level for diagnosis, prognosis, assessment and therapy stratification of corneal nerve damage or loss, corneal neuropathy, corneal neuropathic pain, corneal neuralgia, ocular disease, or peripheral neuropathy.

The invention discloses a novel insect short neuropeptide sNPF analogue and application thereof in pests, and relates to the technical field of agriculture. The invention provides a structural general formula of the novel insect short neuropeptide sNPF analogue, and the novel insect short neuropeptide sNPF analogue is applied to prevention and control of aphids, thrips, plutella xylostella and spodoptera frugiperda. According to the novel insect short neuropeptide sNPF analogue disclosed by the invention, terminal tyrosine Y, arginine R or leucine L residues are substituted and modified by hydrophilic, hydrophobic and steric hindrance natural amino acid or non-natural amino acid and other groups of a lead compound, and the obtained novel insect short neuropeptide sNPF analogue can be used for preventing and treating various pests.

The invention discloses a biological material for promoting optic nerve injury repair and a preparation method thereof.The biological material comprises a bionic nerve scaffold, a growth factor compound, an anti-inflammatory component and a light-operated neuroelectric signal guiding layer, the bionic nerve scaffold comprises a polycaprolactone-polyethylene glycol block copolymer and self-assembly neuropeptide, the growth factor compound comprises a neurosynaptic growth factor and a vascular endothelial growth factor, the anti-inflammatory component is liposome nanoparticles loaded with interleukin-10, and the light-operated neuroelectric signal guide layer is a polypyrrole film; the oriented nanofiber scaffold of polycaprolactone-polyethylene glycol and self-assembled neuropeptide is prepared by adopting a micro-fluidic spinning technology, a three-dimensional porous scaffold is formed to simulate a natural nerve bundle topological structure and guide oriented regeneration of axons, long-acting slow release is realized through gene activated growth factors, the axon extension efficiency is effectively improved, and the growth rate of the axons is increased. Through the interleukin-10 lipidosome anti-inflammatory component, the inflammation inhibition rate is increased, and secondary injury is relieved.

The application discloses a neurotransmitter regulation interaction relationship model construction method and system, relates to the technical field of computational neuroscience, and comprises the following steps: constructing a neuron multimodal neurotransmitter co-release dynamics unit, defining small molecule neurotransmitter and neuropeptide respective vesicle pool state variables, and establishing a coupling release equation based on calcium dependence and regulatory protein selectivity, and outputting two types of neurotransmitter spatiotemporal release source terms; inputting the spatiotemporal release source terms into a three-dimensional brain space structure embedded with a receptor density map, solving a volume conduction equation, and generating a dynamic concentration field of a whole brain range of modulating neurotransmitters; according to a corresponding relationship between the dynamic concentration field and the local receptor density, calculating diffuse modulation input received by the neuron; based on the concentration of a specific modulating neurotransmitter in the dynamic concentration field, driving state evolution of an astrocyte cell unit, and outputting a concentration of a regulatory neurotransmitter released by the astrocyte cell; and integrating point-to-point synapse input, diffuse modulation input and the concentration of the regulatory neurotransmitter released by the astrocyte cell.

The invention relates to recombinant expression constructs comprising a polynucleotide encoding at least one insecticidal neuropeptide, or a precursor peptide thereof, operably linked to a polynucleotide comprising a promoter suitable for expression in a microorganism. The invention also relates to insecticidal neuropeptide precursors, improved methods of their production and use in plant protection. Composition comprising concatemers of insecticidal neuropeptides or precursor peptides thereof are provided.

The disclosure provides a neural peptide prediction method and system based on sequence representation and multi-task learning, relating to the technical fields of biological information and artificial intelligence, comprising: obtaining a peptide amino acid sequence to be predicted; inputting the amino acid sequence into a neural peptide predictor, converting the amino acid sequence into a residue context representation through a sequence representation module of the neural peptide predictor, inputting the residue context representation into a sequence encoding module to capture context dependence at different positions and learn neural peptide discriminative features, and obtaining a feature matrix; aggregating the feature matrix through a feature aggregation module to obtain a fixed-length sequence-level vector; and a classification task module outputting whether the sequence belongs to a neural peptide according to the fixed-length sequence-level vector, and finally completing the prediction of the neural peptide. The disclosure improves the accuracy, robustness and cross-dataset generalization ability of neural peptide prediction.

The invention relates to the technical field of animal model construction, in particular to an animal model for inducing non-allergic rhinitis by temperature change, a method for constructing the animal model and a new scheme for researching an inflammation mechanism of the animal model, and particularly relates to a method for constructing the animal model for inducing non-allergic rhinitis by temperature change. The invention intends to re-cognize upper airway hyperresponsiveness diseases from the perspective of peripheral neuroimmunology, explore a new modeling method of NAR mice, and aims to induce non-allergic rhinitis by using temperature change, deepen cognition of NAR specific pathogenesis, study a specific mechanism of neuropeptide rise, strive to achieve the purpose of diagnosing and treating rhinitis according to the principle of precision medicine, and provide a new model for the NAR mice. An animal model and an animal experiment basis are provided for new clinical treatment in the future, and the method comprises a grouping step, an experiment step and an animal model evaluation setting step.